Tag Archives: MLND

Roth Capital Reiterates Buy on Millendo Therapeutics Shares, Sees 197% Upside For The Stock

In a research report sent to investors on 5/8, Roth Capital analyst Yasmeen Rahimi reiterated a Buy rating on Millendo Therapeutics (NASDAQ:MLND)with a price target of $6, which represents a potential upside of 197% from where the stock is currently

Leerink Partners Thinks Millendo Therapeutics’ Stock is Going to Recover

In a report issued on May 8, Joseph Schwartz from Leerink Partners reiterated an Outperform rating on Millendo Therapeutics (NASDAQ: MLND), with a price target of $5.00. The company’s shares closed last Friday at $2.02, close to its 52-week low

Oppenheimer Remains a Hold on Millendo Therapeutics (MLND)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Millendo Therapeutics (MLND – Research Report), with a price target of $2.00. The company’s shares closed last Wednesday at $1.96, close to its 52-week low of

Millendo Therapeutics (MLND) Gets a Hold Rating from Oppenheimer

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Millendo Therapeutics (MLND – Research Report), with a price target of $2.00. The company’s shares closed last Monday at $1.45. According to TipRanks.com, Olson ‘s ranking

Oppenheimer Maintains Their Buy Rating on Millendo Therapeutics (MLND)

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Millendo Therapeutics (MLND – Research Report). The company’s shares closed last Monday at $6.10, close to its 52-week low of $4.56. According to TipRanks.com, Olson is

Millendo Therapeutics (MLND) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on Millendo Therapeutics (MLND – Research Report) today and set a price target of $25.00. The company’s shares closed last Monday at $6.58, close to its 52-week low of $4.56. According to